J&J’s Tremfya fails giant cell arteritis study, where Roche and AbbVie have succeeded

Johnson & Johnson’s streak of trial wins for its blockbuster drug Tremfya has come to an end.

The blockbuster drug failed in a Phase 2 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Cybin – The Most Explosive Potential Pharmaceutical Company After LLY and NVO – Biotech Investments

EQS Newswire / 19/06/2024 / 21:51 EST/EDT In the past, many notable figures have suffered from depression, with some even taking their own lives, earning

June 21, 2024

Flexitarian diet linked to lower cardiovascular risk, study finds

Study compares cardiovascular risk factors among flexitarians, vegans, and omnivores, finding that plant-based diets may offer significant health benefits.

February 14, 2024

Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III

August 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.